Literature DB >> 18538732

Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Junping Wei1, Mark Wunderlich, Catherine Fox, Sara Alvarez, Juan C Cigudosa, Jamie S Wilhelm, Yi Zheng, Jose A Cancelas, Yi Gu, Michael Jansen, Jorge F Dimartino, James C Mulloy.   

Abstract

Faithful modeling of mixed-lineage leukemia in murine cells has been difficult to achieve. We show that expression of MLL-AF9 in human CD34+ cells induces acute myeloid, lymphoid, or mixed-lineage leukemia in immunodeficient mice. Some leukemia stem cells (LSC) were multipotent and could be lineage directed by altering either the growth factors or the recipient strain of mouse, highlighting the importance of microenvironmental cues. Other LSC were strictly lineage committed, demonstrating the heterogeneity of the stem cell compartment in MLL disease. Targeting the Rac signaling pathway by pharmacologic or genetic means resulted in rapid and specific apoptosis of MLL-AF9 cells, suggesting that the Rac signaling pathway may be a valid therapeutic target in MLL-rearranged AML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538732      PMCID: PMC2486365          DOI: 10.1016/j.ccr.2008.04.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  44 in total

1.  Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells.

Authors:  F C Yang; R Kapur; A J King; W Tao; C Kim; J Borneo; R Breese; M Marshall; M C Dinauer; D A Williams
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.

Authors:  Chi Wai So; Min Lin; Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

4.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.

Authors:  M Feuring-Buske; B Gerhard; J Cashman; R K Humphries; C J Eaves; D E Hogge
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

5.  MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.

Authors:  Chi Wai So; Holger Karsunky; Emmanuelle Passegué; Antonio Cozzio; Irving L Weissman; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

6.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Authors:  Scott A Armstrong; Jane E Staunton; Lewis B Silverman; Rob Pieters; Monique L den Boer; Mark D Minden; Stephen E Sallan; Eric S Lander; Todd R Golub; Stanley J Korsmeyer
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

7.  The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.

Authors:  Jorge F DiMartino; Paul M Ayton; Everett H Chen; Clarissa C Naftzger; Bryan D Young; Michael L Cleary
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Bipotential B-macrophage progenitors are present in adult bone marrow.

Authors:  E Montecino-Rodriguez; H Leathers; K Dorshkind
Journal:  Nat Immunol       Date:  2001-01       Impact factor: 25.606

9.  The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell.

Authors:  B B Zeisig; M P García-Cuéllar; T H Winkler; R K Slany
Journal:  Oncogene       Date:  2003-03-20       Impact factor: 9.867

10.  MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Authors:  M C Stubbs; Y M Kim; A V Krivtsov; R D Wright; Z Feng; J Agarwal; A L Kung; S A Armstrong
Journal:  Leukemia       Date:  2007-09-13       Impact factor: 11.528

View more
  159 in total

1.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

2.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 3.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

4.  MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.

Authors:  Agnieszka Jaracz-Ros; Daniel Lewandowski; Vilma Barroca; Catherine Lavau; Paul-Henri Roméo
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

5.  Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.

Authors:  Monique A Morrison; Richard J Morreale; Shailaja Akunuru; Matthew Kofron; Yi Zheng; Susanne I Wells
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 6.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

7.  The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Authors:  Shan Lin; Roger T Luo; Mahesh Shrestha; Michael J Thirman; James C Mulloy
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

8.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

9.  Rac guanosine triphosphatases represent a potential target in AML.

Authors:  L U W Müller; R J Schore; Y Zheng; E K Thomas; M-O Kim; J A Cancelas; Y Gu; D A Williams
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

10.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Authors:  David C Taussig; Jacques Vargaftig; Farideh Miraki-Moud; Emmanuel Griessinger; Kirsty Sharrock; Tina Luke; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.